April 24, 2024 11:06 AM EDT
News Briefing

Centes­sa's pub­lic of­fer­ing; Vivory­on ends Ph2 Alzheimer’s tri­al

ENDPOINTS

Plus, news about EXO Bi­o­log­ics:

Centes­sa prices pub­lic of­fer­ing: The start­up aims to raise $93.5 mil­lion, or up to $107.6 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times